Compare NOA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOA | BCYC |
|---|---|---|
| Founded | 1953 | 2009 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.9M | 360.7M |
| IPO Year | 2006 | 2019 |
| Metric | NOA | BCYC |
|---|---|---|
| Price | $14.55 | $4.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | 80.9K | ★ 398.3K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.77 | N/A |
| Revenue Next Year | $5.43 | N/A |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.07 | $4.24 |
| 52 Week High | $18.24 | $9.36 |
| Indicator | NOA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 43.32 |
| Support Level | $13.26 | $4.52 |
| Resistance Level | $14.61 | $5.41 |
| Average True Range (ATR) | 0.47 | 0.22 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 70.63 | 25.90 |
North American Construction Group Ltd is Canada's heavy civil construction and mining contractor provider. The company has provided services to oil, natural gas, and resource companies. The Company provides a wide range of mining and heavy civil construction services to customer in the resource development and industrial construction sectors within Canada, the United States, and Australia. The Company's reportable segments are Heavy Equipment Canada, Heavy Equipment Australia, and Other. Heavy Equipment Canada and Heavy Equipment Australia include all of aspects of the mining and heavy civil construction services provided within those geographic areas. Other includes mine management contract work in the United States, its external maintenance and rebuild programs.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.